
Vertex Pharmaceuticals Incorporated: shareholders and insiders
Price
$538.60
November 13, 2026Market cap $137B
What Ploutos Investor adds for Vertex Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 16, 2025 to Nov 10, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$132M
13 people
From Nov 16, 2025 to Nov 16, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 16, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $94M by 12 people
- 2025: no buys, sold $38M by 5 people
- 2026: no buys, sold $94M by 12 people
- Nov 6, 2026Reshma KewalramaniCEO & PresidentKind10b5-1
- Oct 20, 2026Daniel J. BrennanDirectorKind
- Sep 8, 2026Grunsven Jasper vanEVP, CP and NPPOKind
- Aug 28, 2026Kristen AmbroseSVP & Chief Accounting OfficerKind
- Aug 27, 2026Bruce I SachsDirectorKind
- Jul 21, 2026Ourania TatsisEVP, Chief Reg. & Quality Off.Kind
- Jul 21, 2026Amit SachdevEVP Chief Patient & Ext Af OffKind
- Jul 2, 2026Ourania TatsisEVP, Chief Reg. & Quality Off.Kind10b5-1
- Jul 2, 2026Duncan McKechnieEVP, Chief Commercial OfficerKind10b5-1
- Jul 1, 2026Joy LiuEVP and Chief Legal OfficerKind10b5-1
- Jun 26, 2026Carmen BozicEVP and CMOKind10b5-1
- Jun 18, 2026Carmen BozicEVP and CMOKind10b5-1
- Jun 15, 2026Carmen BozicEVP and CMOKind10b5-1
- Jun 5, 2026Carmen BozicEVP and CMOKind10b5-1
- Jun 1, 2026Joy LiuEVP and Chief Legal OfficerKind10b5-1
- May 29, 2026Carmen BozicEVP and CMOKind10b5-1
- May 15, 2026Carmen BozicEVP and CMOKind10b5-1
- May 15, 2026Mark E. BunnageEVP, Chief Scientific OfficerKind10b5-1
- May 12, 2026Carmen BozicEVP and CMOKind10b5-1
- May 4, 2026Sangeeta N. BhatiaKind10b5-1
- May 1, 2026Joy LiuEVP and Chief Legal OfficerKind10b5-1
- Apr 1, 2026Joy LiuEVP and Chief Legal OfficerKind10b5-1
- Mar 27, 2026Carmen BozicEVP and CMOKind10b5-1
- Mar 13, 2026Carmen BozicEVP and CMOKind10b5-1
- Mar 11, 2026Duncan McKechnieEVP, Chief Commercial OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | Reshma KewalramaniCEO & President | 10b5-1 | 11.9K | $531.53 | $6.3M | Form 4 |
| Oct 20, 2026 | Daniel J. BrennanDirector | 795 | $503.47 | $400.3K | Form 4 | |
| Sep 8, 2026 | Grunsven Jasper vanEVP, CP and NPPO | 8,682 | – | – | Form 4 | |
| Aug 28, 2026 | Kristen AmbroseSVP & Chief Accounting Officer | 5,000 | – | – | Form 4 | |
| Aug 27, 2026 | Bruce I SachsDirector | 6,000 | – | – | Form 4 | |
| Jul 21, 2026 | Ourania TatsisEVP, Chief Reg. & Quality Off. | 8,251 | – | – | Form 4 | |
| Jul 21, 2026 | Amit SachdevEVP Chief Patient & Ext Af Off | 8,251 | – | – | Form 4 | |
| Jul 2, 2026 | Ourania TatsisEVP, Chief Reg. & Quality Off. | 10b5-1 | 1,500 | $524.99 | $787.5K | Form 4 |
| Jul 2, 2026 | Duncan McKechnieEVP, Chief Commercial Officer | 10b5-1 | 1,541 | $519.00 | $799.8K | Form 4 |
| Jul 1, 2026 | Joy LiuEVP and Chief Legal Officer | 10b5-1 | 828 | $502.71 | $416.2K | Form 4 |
| Jun 26, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 596 | $482.50 | $287.6K | Form 4 |
| Jun 18, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 1,020 | $462.17 | $471.4K | Form 4 |
| Jun 15, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 4,062 | $450.00 | $1.8M | Form 4 |
| Jun 5, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 1,745 | $450.00 | $785.3K | Form 4 |
| Jun 1, 2026 | Joy LiuEVP and Chief Legal Officer | 10b5-1 | 828 | $439.91 | $364.2K | Form 4 |
| May 29, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 1,974 | $450.00 | $888.3K | Form 4 |
| May 15, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 1,354 | $453.45 | $614.0K | Form 4 |
| May 15, 2026 | Mark E. BunnageEVP, Chief Scientific Officer | 10b5-1 | 33 | $453.45 | $15.0K | Form 4 |
| May 12, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 6,988 | $450.00 | $3.1M | Form 4 |
| May 4, 2026 | Sangeeta N. Bhatia | 10b5-1 | 318 | $423.73 | $134.7K | Form 4 |
| May 1, 2026 | Joy LiuEVP and Chief Legal Officer | 10b5-1 | 1,104 | $425.02 | $469.2K | Form 4 |
| Apr 1, 2026 | Joy LiuEVP and Chief Legal Officer | 10b5-1 | 978 | $449.17 | $439.3K | Form 4 |
| Mar 27, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 2,329 | $450.95 | $1.1M | Form 4 |
| Mar 13, 2026 | Carmen BozicEVP and CMO | 10b5-1 | 2,329 | $481.79 | $1.1M | Form 4 |
| Mar 11, 2026 | Duncan McKechnieEVP, Chief Commercial Officer | 10b5-1 | 2,633 | $498.42 | $1.3M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by VRTX's officers and directors from 2004 up to November 15, 2025, 22 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 17 more, back to 2004
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Capital World InvestorsShare of class10.1%
- Capital Research Global InvestorsShare of class8.30%
- Vanguard Capital ManagementShare of class7.49%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Capital World Investors | 10.1% | 25.70M | May 14, 20262 filings since Feb 13, 2025 | 13G/A | |
| Capital Research Global Investors | 8.30% | 21.14M | May 14, 20263 filings since May 13, 2025 | 13G/A | |
| Vanguard Capital Management | 7.49% | 19.04M | Apr 30, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter+24%
- Millennium Mgmt (Englander)In the quarter×15.2
- Citadel Advisors (Griffin)In the quarter+50%
- AQR CapitalIn the quarter+260%
- Bridgewater (Dalio)In the quarter-19%
- Point72 (Cohen)In the quarter
- D.E. ShawIn the quarter-99%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 396.8K | +24% | $207M | 0.28% |
| Millennium Mgmt (Englander) | 468.4K | ×15.2 | $233M | 0.16% |
| Citadel Advisors (Griffin) | 510.4K | +50% | $254M | 0.15% |
| AQR Capital | 616.2K | +260% | $305M | 0.11% |
| Bridgewater (Dalio) | 10.9K | -19% | $5.4M | 0.02% |
| Point72 (Cohen) | 2,625 | $1.3M | 0.00% | |
| D.E. Shaw | 3,105 | -99% | $1.5M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 1.68% of its shares outstanding were held short, -5.3% since the report before.
- Shares held short
- 4.26M
- 1.68%
- Since the report before4.50M on Sep 30, 2026
- -5.3%
- 3.4
- 1.26M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 40%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 2.60M
- Nov 15, 2023: Shares held short 2.51M
- Nov 30, 2023: Shares held short 2.69M
- Dec 15, 2023: Shares held short 3.55M
- Dec 29, 2023: Shares held short 3.26M
- Jan 12, 2024: Shares held short 3.35M
- Jan 31, 2024: Shares held short 3.31M
- Feb 15, 2024: Shares held short 4.13M
- Feb 29, 2024: Shares held short 4.05M
- Mar 15, 2024: Shares held short 4.13M
- Mar 28, 2024: Shares held short 3.98M
- Apr 15, 2024: Shares held short 4.03M
- Apr 30, 2024: Shares held short 3.87M
- May 15, 2024: Shares held short 3.77M
- May 31, 2024: Shares held short 4.35M
- Jun 14, 2024: Shares held short 4.47M
- Jun 28, 2024: Shares held short 4.10M
- Jul 15, 2024: Shares held short 4.12M
- Jul 31, 2024: Shares held short 5.08M
- Aug 15, 2024: Shares held short 4.42M
- Aug 30, 2024: Shares held short 4.38M
- Sep 13, 2024: Shares held short 4.34M
- Sep 30, 2024: Shares held short 4.08M
- Oct 15, 2024: Shares held short 4.29M
- Oct 31, 2024: Shares held short 4.50M
- Nov 15, 2024: Shares held short 4.11M
- Nov 29, 2024: Shares held short 3.67M
- Dec 13, 2024: Shares held short 3.51M
- Dec 31, 2024: Shares held short 3.96M
- Jan 15, 2025: Shares held short 4.39M
- Jan 31, 2025: Shares held short 4.56M
- Feb 14, 2025: Shares held short 5.07M
- Feb 28, 2025: Shares held short 5.48M
- Mar 14, 2025: Shares held short 5.75M
- Mar 31, 2025: Shares held short 4.46M
- Apr 15, 2025: Shares held short 4.37M
- Apr 30, 2025: Shares held short 3.78M
- May 15, 2025: Shares held short 4.82M
- May 30, 2025: Shares held short 4.41M
- Jun 13, 2025: Shares held short 4.03M
- Jun 30, 2025: Shares held short 4.39M
- Jul 15, 2025: Shares held short 4.19M
- Jul 31, 2025: Shares held short 4.36M
- Aug 15, 2025: Shares held short 3.70M
- Aug 29, 2025: Shares held short 3.64M
- Sep 15, 2025: Shares held short 4.05M
- Sep 30, 2025: Shares held short 3.56M
- Oct 15, 2025: Shares held short 3.56M
- Oct 31, 2025: Shares held short 4.13M
- Nov 14, 2025: Shares held short 4.01M
- Nov 28, 2025: Shares held short 4.46M
- Dec 15, 2025: Shares held short 4.29M
- Dec 31, 2025: Shares held short 5.02M
- Jan 15, 2026: Shares held short 4.42M
- Jan 30, 2026: Shares held short 4.42M
- Feb 13, 2026: Shares held short 4.47M
- Feb 27, 2026: Shares held short 4.43M
- Mar 13, 2026: Shares held short 4.13M
- Mar 31, 2026: Shares held short 4.02M
- Apr 15, 2026: Shares held short 4.34M
- Apr 30, 2026: Shares held short 4.17M
- May 15, 2026: Shares held short 4.46M
- May 29, 2026: Shares held short 4.49M
- Jun 15, 2026: Shares held short 4.62M
- Jun 30, 2026: Shares held short 4.94M
- Jul 15, 2026: Shares held short 4.99M
- Jul 31, 2026: Shares held short 3.94M
- Aug 14, 2026: Shares held short 4.15M
- Aug 31, 2026: Shares held short 4.66M
- Sep 15, 2026: Shares held short 4.72M
- Sep 30, 2026: Shares held short 4.50M
- Oct 15, 2026: Shares held short 4.26M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading60.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 60.9% of the shares in the reported trades were short sales, against 42.7% in the 14 before.
- Last 14 sessionsOct 27, 2026 – Nov 13, 2026
- 60.9%
- The 14 beforeOct 7, 2026 – Oct 26, 2026
- 42.7%
- Change
- +18.2 pts
- Short sales a dayon average, of 559.2K shares
- 340.8K
- More than atof 3,649 US-listed companies, same days
- 86%
- Median of alleight in ten from 34.6% to 63.4%
- 50.1%
- Short sales
- Oct 7, 2026: Short sales 54.6%
- Oct 8, 2026: Short sales 42.5%
- Oct 9, 2026: Short sales 31%
- Oct 12, 2026: Short sales 36.6%
- Oct 13, 2026: Short sales 59%
- Oct 14, 2026: Short sales 40.4%
- Oct 15, 2026: Short sales 29.9%
- Oct 16, 2026: Short sales 40.1%
- Oct 19, 2026: Short sales 29.3%
- Oct 20, 2026: Short sales 29.2%
- Oct 21, 2026: Short sales 50.9%
- Oct 22, 2026: Short sales 64.5%
- Oct 23, 2026: Short sales 58.4%
- Oct 26, 2026: Short sales 55.3%
- Oct 27, 2026: Short sales 49.4%
- Oct 28, 2026: Short sales 66.5%
- Oct 29, 2026: Short sales 61.4%
- Oct 30, 2026: Short sales 71.7%
- Nov 2, 2026: Short sales 70.4%
- Nov 3, 2026: Short sales 60.1%
- Nov 4, 2026: Short sales 58.1%
- Nov 5, 2026: Short sales 63.1%
- Nov 6, 2026: Short sales 52.9%
- Nov 9, 2026: Short sales 46.9%
- Nov 10, 2026: Short sales 54%
- Nov 11, 2026: Short sales 43.8%
- Nov 12, 2026: Short sales 60.2%
- Nov 13, 2026: Short sales 45.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Reshma KewalramaniCEO & PresidentDirectly86.5K
- Jeffrey M LeidenExecutive ChairmanDirectly75.2K
- Amit SachdevEVP Chief Patient & Ext Af OffDirectly74.0K
- Ourania TatsisEVP, Chief Reg. & Quality Off.Directly53.6K
- Stuart A ArbuckleEVP, COODirectly49.7K
- Bruce I SachsDirectorDirectly39.0K
- Charles F Wagner JrEVP, CO & FODirectly37.7K
- David AltshulerEVP, Chief Scientific OfficerDirectly23.3K
- Joy LiuEVP and Chief Legal OfficerDirectly19.1K
- Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off.Directly18.4K
- Carmen BozicEVP and CMODirectly15.3K
- Jonathan BillerEVP and Chief Legal OfficerDirectly13.7K
- Kristen AmbroseSVP & Chief Accounting OfficerDirectly11.6K
- Duncan McKechnieEVP, Chief Commercial OfficerDirectly11.0K
- Grunsven Jasper vanEVP, CP and NPPODirectly8,682
- Mark E. BunnageEVP, Chief Scientific OfficerDirectly7,284
- Sangeeta N. BhatiaDirectorDirectly4,924
- Daniel J. BrennanDirectorDirectly795
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Reshma KewalramaniCEO & President | 86.5K | – | Nov 6, 2026 | Form 4 |
| Jeffrey M LeidenExecutive Chairman | 75.2K | – | Dec 3, 2025 | Form 4 |
| Amit SachdevEVP Chief Patient & Ext Af Off | 74.0K | – | Jul 21, 2026 | Form 4 |
| Ourania TatsisEVP, Chief Reg. & Quality Off. | 53.6K | – | Jul 21, 2026 | Form 4 |
| Stuart A ArbuckleEVP, COO | 49.7K | – | May 15, 2024 | Form 4 |
| Bruce I SachsDirector | 39.0K | – | Aug 27, 2026 | Form 4 |
| Charles F Wagner JrEVP, CO & FO | 37.7K | – | Jan 6, 2026 | Form 4 |
| David AltshulerEVP, Chief Scientific Officer | 23.3K | – | May 15, 2025 | Form 4 |
| Joy LiuEVP and Chief Legal Officer | 19.1K | – | Jul 1, 2026 | Form 4 |
| Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off. | 18.4K | – | Feb 25, 2026 | Form 4 |
| Carmen BozicEVP and CMO | 15.3K | – | Jun 26, 2026 | Form 4 |
| Jonathan BillerEVP and Chief Legal Officer | 13.7K | – | Feb 25, 2026 | Form 4 |
| Kristen AmbroseSVP & Chief Accounting Officer | 11.6K | – | Aug 28, 2026 | Form 4 |
| Duncan McKechnieEVP, Chief Commercial Officer | 11.0K | – | Jul 2, 2026 | Form 4 |
| Grunsven Jasper vanEVP, CP and NPPO | 8,682 | – | Sep 8, 2026 | Form 4 |
| Mark E. BunnageEVP, Chief Scientific Officer | 7,284 | – | May 15, 2026 | Form 4 |
| Sangeeta N. BhatiaDirector | 4,924 | – | May 4, 2026 | Form 4 |
| Daniel J. BrennanDirector | 795 | – | Oct 20, 2026 | Form 4 |
A lower bound: it counts only the 18 officers and directors with a market trade since Nov 17, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Alan GarberDirectorWhat happenedAdoptedAug 27, 2026Shares5,320
- Bruce SachsDirectorWhat happenedAdoptedAug 26, 2026Shares9,888
- Joy LiuEVP, Chief Legal OfficerWhat happenedAdoptedAug 21, 2026Shares20.8K
- Nancy ThornberryDirectorWhat happenedAdoptedAug 15, 2026Shares2,571
- Sangeeta BhatiaDirectorWhat happenedAdoptedAug 13, 2026Shares1,189
- Charles F. Wagner, Jr.EVP, Chief Operating & Financial OfficerWhat happenedAdoptedAug 10, 2026Shares15.3K
- Carmen BozicEVP, Global Medicines Development and Medical Affairs, and Chief Medical OfficerWhat happenedAdoptedAug 6, 2026Shares16.9K
- Kristen AmbroseSVP, Chief Accounting OfficerWhat happenedAdoptedAug 6, 2026Shares5,422
- Jeffrey LeidenExecutive ChairmanWhat happenedAdoptedAug 5, 2026Shares18.4K
- Reshma KewalramaniChief Executive Officer and President, DirectorWhat happenedAdoptedAug 5, 2026Shares47.8K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Alan GarberDirector | AdoptedAug 27, 2026 | Jul 30, 2027 | 5,320 | 10-Q |
| Bruce SachsDirector | AdoptedAug 26, 2026 | Jul 20, 2027 | 9,888 | 10-Q |
| Joy LiuEVP, Chief Legal Officer | AdoptedAug 21, 2026 | May 3, 2027 | 20.8K | 10-Q |
| Nancy ThornberryDirector | AdoptedAug 15, 2026 | Jul 30, 2027 | 2,571 | 10-Q |
| Sangeeta BhatiaDirector | AdoptedAug 13, 2026 | Jul 30, 2027 | 1,189 | 10-Q |
| Charles F. Wagner, Jr.EVP, Chief Operating & Financial Officer | AdoptedAug 10, 2026 | Jul 30, 2027 | 15.3K | 10-Q |
| Carmen BozicEVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer | AdoptedAug 6, 2026 | Jul 30, 2027 | 16.9K | 10-Q |
| Kristen AmbroseSVP, Chief Accounting Officer | AdoptedAug 6, 2026 | Apr 30, 2027 | 5,422 | 10-Q |
| Jeffrey LeidenExecutive Chairman | AdoptedAug 5, 2026 | Nov 4, 2027 | 18.4K | 10-Q |
| Reshma KewalramaniChief Executive Officer and President, Director | AdoptedAug 5, 2026 | Dec 1, 2027 | 47.8K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$21M
Actually paid: $38M
$7.7M
Actually paid: $13M
$192
Peers: $125
net product revenue
$12.0B
From the proxy statement (DEF 14A) of Apr 2, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-QAmount$455M
- Mar 31, 202610-QAmount$344M
- Dec 31, 202510-KAmount$105M
- Sep 30, 202510-QAmount$1.1B
- Jun 30, 202510-QAmount$395M
- Mar 31, 202510-QAmount$417M
- Dec 31, 202410-KAmount$427M
- Sep 30, 202410-QAmount$308M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-Q | 1.03M | $440.17 | $455M | $2.6B | 10-Q |
| Mar 31, 202610-Q | 741.1K | $464.79 | $344M | $3.0B | 10-Q |
| Dec 31, 202510-K | 256.8K | $409.11 | $105M | $3.4B | 10-K |
| Sep 30, 202510-Q | 2.73M | $397.11 | $1.1B | $3.5B | 10-Q |
| Jun 30, 202510-Q | 868.7K | $454.12 | $395M | $4.6B | 10-Q |
| Mar 31, 202510-Q | 932.5K | $447.03 | $417M | $964M | 10-Q |
| Dec 31, 202410-K | 961.1K | $444.63 | $427M | $1.4B | 10-K |
| Sep 30, 202410-Q | 640.0K | $480.60 | $308M | $1.8B | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 1 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026May 13, 2026For93.5%
- 2025May 14, 2025For92.5%
- 2024May 15, 2024For91.3%
- 2023May 18, 2023For89.5%
- 2022May 18, 2022For92.6%
- 2021May 19, 2021For91.4%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026May 13, 2026 | 93.5% | 208M | 14.52M | 556.0K | 10.34M | 8-K |
| 2025May 14, 2025 | 92.5% | 209M | 17.05M | 307.6K | 10.24M | 8-K |
| 2024May 15, 2024 | 91.3% | 202M | 19.22M | 875.8K | 11.54M | 8-K |
| 2023May 18, 2023 | 89.5% | 201M | 23.64M | 155.6K | 9.83M | 8-K |
| 2022May 18, 2022 | 92.6% | 202M | 16.11M | 1.70M | 9.81M | 8-K |
| 2021May 19, 2021 | 91.4% | 201M | 18.82M | 176.5K | 11.02M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund8.08%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund2.19%
- CGGRCapital Group Growth ETFWeight in the fund2.03%
- IYHiShares U.S. Healthcare ETFWeight in the fund2.00%
- VHTVanguard Health Care Index FundWeight in the fund1.92%
- CGUSCapital Group Core Equity ETFWeight in the fund1.90%
- IXJiShares Global Healthcare ETFWeight in the fund1.64%
- CGGOCapital Group Global Growth Equity ETFWeight in the fund1.62%
- USMViShares MSCI USA Min Vol Factor ETFWeight in the fund1.46%
- CGBLCapital Group Core Balanced ETFWeight in the fund1.20%
48 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 1,523
- Q4 2025: Managers 1,671
- Q1 2026: Managers 1,701
- Q2 2026: Managers 1,756
Institutional investors by quarter
The fund managers holding VRTX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 1,756 managers held 242M shares, worth $120B. During the quarter 192 opened a position, 137 closed one, 697 added and 610 trimmed.
The largest holders, Q2 2026
- Capital World InvestorsIn the quarter+2.9%
- BlackRockIn the quarter+0.6%
- Capital Research Global InvestorsIn the quarter-7.7%
- Vanguard Capital ManagementIn the quarter+0.4%
- State StreetIn the quarter+1.2%
- InvescoIn the quarter+1.9%
- JPMorgan ChaseIn the quarter-7.3%
- Geode Capital ManagementIn the quarter-2.0%
- Vanguard Portfolio ManagementIn the quarter-5.2%
- Capital International InvestorsIn the quarter-8.4%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Capital World Investors | 26.12M | +2.9% | $13.0B |
| BlackRock | 24.11M | +0.6% | $12.0B |
| Capital Research Global Investors | 19.49M | -7.7% | $9.7B |
| Vanguard Capital Management | 16.58M | +0.4% | $8.2B |
| State Street | 11.87M | +1.2% | $5.9B |
| Invesco | 8.04M | +1.9% | $4.0B |
| JPMorgan Chase | 6.52M | -7.3% | $3.3B |
| Geode Capital Management | 6.02M | -2.0% | $3.0B |
| Vanguard Portfolio Management | 4.88M | -5.2% | $2.4B |
| Capital International Investors | 4.70M | -8.4% | $2.3B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Vertex Pharmaceuticals's filings show?
Who buys and sells is one part of Vertex Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have VRTX's insiders bought or sold?
From Jun 2, 2026 to Nov 10, 2026 Vertex Pharmaceuticals's insiders bought 0 and sold $13M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold VRTX?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $305M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.